Hansen Gwenninsider trades
In SEC Form 4 filings, Hansen Gwenn is listed as Chief Scientific Officer of Nurix Therapeutics, Inc. (NRIX). In the last 90 days, Hansen Gwenn sold $73.3K of Nurix Therapeutics, Inc. (NRIX) on the open market and bought none. All 2 sales were reported under a 10b5-1 trading plan.
Companies and roles
| Company | Role | Transactions | Last filed |
|---|---|---|---|
| NRIXNurix Therapeutics, Inc. | Chief Scientific Officer | 6 | Oct 15 |
Cluster buys
No cluster buy in the last 90 days included a purchase by this insider (two or more insiders buying within 14 days).
Form 4 historysince 2026-09-01
| Company | Traded | Filed | Type | Shares | Price | Value | Owned after | 10b5-1 plan | Filing |
|---|---|---|---|---|---|---|---|---|---|
| NRIXNurix Therapeutics, Inc. | Oct 15 | Oct 15 | M | 1,452 | $1.86 | $2,701 | 118,679 | Yes | Form 4 |
| NRIXNurix Therapeutics, Inc. | Oct 15 | Oct 15 | S | 1,452 | $25.00 | Sale −$36,300 | 117,227 | Yes | Form 4 |
| NRIXNurix Therapeutics, Inc. | Oct 15 | Oct 15 | M · derivative | 1,452 | $1.86 | $2,701 | 59,406 | Yes | Form 4 |
| NRIXNurix Therapeutics, Inc. | Sep 1 | Sep 1 | M | 1,452 | $1.86 | $2,701 | 118,679 | Yes | Form 4 |
| NRIXNurix Therapeutics, Inc. | Sep 1 | Sep 1 | S | 1,452 | $25.47 | Sale −$36,982 | 117,227 | Yes | Form 4 |
| NRIXNurix Therapeutics, Inc. | Sep 1 | Sep 1 | M · derivative | 1,452 | $1.86 | $2,701 | 60,858 | Yes | Form 4 |
Published from this insider's public Form 4 filings on SEC EDGAR; the name is shown as filed. Named in a filing and want this page removed? See the privacy policy.